

Disclosures (Lifetime): Maurizio Fava, MD

Updated: January 2026

****All disclosures can also be viewed online by navigating to: <https://mghcme.org/maurizio-fava-bio-disclosure/>**

Research Support:

Abbott Laboratories; Abbvie; Acadia Pharmaceuticals; Alkermes, Inc.; Alto Neuroscience, Inc.; American Cyanamid; Ancora Bio, Inc.; Aspect Medical Systems; AstraZeneca; Atai Therapeutics, Inc.; Autobahn Therapeutics, Inc.; Avanir Pharmaceuticals; AXSOME Therapeutics; BioClinica, Inc; Biohaven; BioResearch; BioShin Limited; BrainCells Inc.; Bristol-Myers Squibb; CeNeRx BioPharma; Centrexion Therapeutics Corporation; Cephalon; Cerecor; Clarus Funds; Clexio Biosciences, Ltd; Clintara, LLC; Covance; Covidien; Cybin IRL Limited; Damona Pharmaceuticals; Draig Therapeutics Limited; Eli Lilly and Company; Eliem Therapeutics LTD; EmbarkNeuro; EnVivo Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Forest Pharmaceuticals, Inc.; FORUM Pharmaceuticals; Ganeden Biotech, Inc.; Gentelon, LLC; Gerbera Therapeutics, Inc.; GH Research Ireland Limited; Gilgamesh Pharmaceuticals, Inc.; GlaxoSmithKline; Harvard Clinical Research Institute; Hoffman-LaRoche; Icon Clinical Research; Indivior; i3 Innovus/Ingenix; Janssen Research & Development LLC; Janssen Pharmaceutica NV; Jed Foundation; Johnson & Johnson Pharmaceutical Research & Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; Lundbeck Inc.; Marinus Pharmaceuticals; MedAvante; Medpace, Inc.; Methylation Sciences Inc; Mind Medicine Inc.; National Alliance for Research on Schizophrenia & Depression (NARSAD); National Center for Complementary and Alternative Medicine (NCCAM); National Coordinating Center for Integrated Medicine (NiiCM); National Institute of Drug Abuse (NIDA); National Institutes of Health; National Institute of Mental Health (NIMH); Neuralstem, Inc.; NeuraWell Therapeutics, Inc.; Neumora Therapeutics, Inc.; Neurocrine Biosciences, Inc.; NeuroRx; Novartis AG; Novaremed; Organon Pharmaceuticals; Otsuka Pharmaceutical Development, Inc.; PamLab, LLC.; Peachtree BioResearch Solutions Inc.; Pfizer Inc.; Pharmacia-Upjohn; Pharmaceutical Research Associates., Inc.; Pharmavite® LLC; PharmoRx Therapeutics; Photothera; Praxis Precision Medicines; Premiere Research International; Protagenic Therapeutics, Inc.; Reckitt Benckiser; Relmada Therapeutics Inc.; Roche Pharmaceuticals; RCT Logic, LLC (formerly Clinical Trials Solutions, LLC); Sanofi-Aventis US LLC; Seaport Therapeutics, Inc.; Shenox Pharmaceuticals, LLC; Shire; Solvay Pharmaceuticals, Inc.; Stanley Medical Research Institute (SMRI); Synthelabo; Taisho Pharmaceuticals; Takeda Pharmaceuticals; Tal Medical; VistaGen; University of Florida Board of Trustees; WinSanTor, Inc.; Wyeth-Ayerst Laboratories; Xenon Pharmaceuticals, Inc.; XW Pharma Ltd.

Advisory Board / Consultant:

4M Therapeutics, Inc.; Abbott Laboratories; Abbvie; ABVC Biopharma; Acadia; Aditum Bio Management Company, LLC; Affectis Pharmaceuticals AG; Alfasigma USA, Inc.; Aidvance GmbH; Alkermes, Inc.; Altimate Health Corporation; Amarin Pharma Inc.; Amorsa Therapeutics, Inc.; Ancora Bio, Inc.; Angelini S.p.A; Aptinyx Inc.; Arbor Pharmaceuticals, LLC; Aspect Medical Systems; Astella Pharma Global Development, Inc.; AstraZeneca; Atai Therapeutics, Inc.; Atella, Inc; Auspex Pharmaceuticals; Autobahn Therapeutics; Avanir Pharmaceuticals; AXSOME Therapeutics; Bayer AG; Beacon Biosignals, Inc.; Best Practice Project Management, Inc.; Biogen; BioMarin Pharmaceuticals, Inc.; BioXcel Therapeutics; Biovail Corporation; Boehringer Ingelheim International; Boston Pharmaceuticals; BrainCells Inc; Brainify; Bria Biosciences, Inc.; Bristol-Myers Squibb; Cambridge Science Corporation; CeNeRx BioPharma; Cephalon, Inc.; Cerecor; Cerevel Therapeutics, Inc.; Certego Therapeutics; Clexio Biosciences; Click Therapeutics, Inc; CNS Response, Inc.; Compellis Pharmaceuticals; CuraSen Therapeutics, Inc.; Cybin Corporation; Cycleron Therapeutics, Inc.; Cypress Pharmaceutical, Inc.; Delix Therapeutics, Inc.; Denovo Biopharma LLC; DiagnoSearch Life Sciences (P) Ltd.; Dainippon Sumitomo Pharma Co. Inc.; Dr. Katz, Inc.; Dolby Family Ventures Life Sciences, LP; Dov Pharmaceuticals, Inc.; Edgemont Pharmaceuticals, Inc.; Eisai Inc.; Eli Lilly and Company; ElMindA; EmbarkNeuro, Inc.; EnVivo Pharmaceuticals, Inc.; Enveric Biosciences; Enzymotec LTD; ePharmaSolutions; EPIX Pharmaceuticals, Inc.; Esthismos Research, Inc.; Eurofarma Laboratórios S.A; Euthymics Bioscience, Inc.; Evexia Therapeutics, Inc.; ExpertConnect, LLC; FAAH Research Inc.; Fabre-Kramer Pharmaceuticals, Inc.; Fisher Wallace Laboratories, Inc.; Forest Pharmaceuticals, Inc.; Forum Pharmaceuticals; Gaba Therapeutics, Inc.; Gate Neurosciences, Inc.; GenetikaPlus Ltd.; GenOmind, LLC; Gilgamesh Pharma; GlaxoSmithKline; Grunenthal GmbH; Happify; Healis Therapeutics; H. Lundbeck A/S; Indivior; i3 Innovus/Ingenix; Intracellular; Janssen Pharmaceutica; Japan Tobacco Inc; Jazz Pharmaceuticals, Inc.; JDS Therapeutics, LLC;

Johnson & Johnson Pharmaceutical Research & Development, LLC; Journey Colab Corporation; Karuna Therapeutics, Inc.; Knoll Pharmaceuticals Corp.; Labopharm Inc.; LB Pharmaceuticals, Inc.; Lexicon Pharmaceuticals; Lilly USA, LLC; Longboard Pharmaceuticals; Lorex Pharmaceuticals; Lundbeck Inc.; MAPREG; Marinus Pharmaceuticals; MedAvante, Inc.; Merck & Co., Inc.; Mind Medicine Inc.; MSI Methylation Sciences, Inc.; Naurex, Inc.; Navitor Pharmaceuticals, Inc.; Nestle Health Sciences; Neuralstem, Inc.; NeuraWell Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Neuroinnovatech ApS; Neuronetics, Inc.; NextWave Pharmaceuticals; Niraxx Light Therapeutics, Inc.; Northwestern University; Novartis AG; Nutrition 21; Opiant Pharmecuticals; Orexigen Therapeutics, Inc.; Organon Pharmaceuticals; Osmotica; Otsuka Pharmaceuticals; Ovid Therapeutics, Inc.; PamLab, LLC.; Perception Neuroscience; Pfizer Inc.; Pharmapotheca A, Inc.; PharmaStar; PharmaTher Inc.; Pharmavite® LLC.; Pharmorx Therapeutics; Polaris Partners; Praxis Precision Medicines; Precision Human Biolaboratory; Prexa Pharmaceuticals, Inc.; Primetime Life Sciences, LLC; Protagenic Therapeutics, Inc; PPD; PThera, LLC; Purdue Pharma; Puretech Ventures; PureTech LYT, Inc.; PsychoGenics; Psylin Neurosciences, Inc.; RCT Logic, LLC (formerly Clinical Trials Solutions, LLC); Relmada Therapeutics, Inc.; Reset Pharma; Rexahn Pharmaceuticals, Inc.; Ridge Diagnostics, Inc.; Roche; Sage Therapeutics, Inc.; Sanofi-Aventis US LLC.; Seed Health, Inc.; Sensorium Therapeutics; Sentier Therapeutics; Sepracor Inc.; Servier Laboratories; Schering-Plough Corporation; Shenox Pharmaceuticals, LLC; Solvay Pharmaceuticals, Inc.; Somaxon Pharmaceuticals, Inc.; Somerset Pharmaceuticals, Inc.; Sonde Health; Sunovion Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Synthelabo; Taisho Pharmaceuticals; Takeda Pharmaceutical Company Limited; Tal Medical, Inc.; Tetragenex; Teva Pharmaceuticals; Tonix Pharmaceuticals; TransForm Pharmaceuticals, Inc.; Transcept Pharmaceuticals, Inc.; University of Michigan, Department of Psychiatry; Usona Institute, Inc.; Vanda Pharmaceuticals, Inc.; Verb Biotics, LLC; Versant Venture Management, LLC; Vertex Pharmaceuticals Incorporated; Vida Ventures III, LP; VistaGen; Xenon Pharmaceuticals Inc.; Xylo Bio.

Dr. Fava has not done any personal consulting for the past 19 years. Any consulting he has done has been on behalf of Massachusetts General Hospital, except for Revival Therapeutics (no longer in existence) and Sensorium Therapeutics.

Speaking/Publishing:

Adamed, Co; Advanced Meeting Partners; American Psychiatric Association; American Society of Clinical Psychopharmacology; AstraZeneca; Belvoir Media Group; Boehringer Ingelheim GmbH; Bristol-Myers Squibb; Cephalon, Inc.; CME Institute/Physicians Postgraduate Press, Inc.; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Global Medical Education, Inc.; Imedex, LLC; MGH Psychiatry Academy/Primedia; MGH Psychiatry Academy/Reed Elsevier; Novartis AG; Organon Pharmaceuticals; Pfizer Inc.; PharmaStar; United BioSource, Corp.; Wyeth-Ayerst Laboratories.

Stock/Other Financial Options:

Equity Holdings: Compellis (no longer in existence); Neuromity; Psy Therapeutics; Revival Therapeutics (no longer in existence); Sensorium Therapeutics.

Royalty/patent, other income: Patents for Sequential Parallel Comparison Design (SPCD), licensed by MGH to Pharmaceutical Product Development, LLC (PPD) (US_7840419, US_7647235, US_7983936, US_8145504, US_8145505); patent application for a combination of Ketamine plus Scopolamine in Major Depressive Disorder (MDD), licensed by MGH to Biohaven; and patents for pharmacogenomics of Depression Treatment with Folate (US_9546401, US_9540691) licensed to Nestle and for Compound for improving L-arginine bioavailability (US_11,655,210) licensed to DimeRx.

Copyright for the MGH Cognitive & Physical Functioning Questionnaire (CPFQ), Sexual Functioning Inventory (SFI), Antidepressant Treatment Response Questionnaire (ATRQ), Discontinuation-Emergent Signs & Symptoms (DESS), Symptoms of Depression Questionnaire (SDQ), Anxiety Symptoms Questionnaire (ASQ), and SAFER; Belvoir; Lippincott, Williams & Wilkins; Wolters Kluwer; World Scientific Publishing Co. Pte.Ltd.